Respiratory syncytial virus (RSV) is one of the leading causes of respiratory tract infections in young children and is associated with severe respiratory disease in people aged over 60 years.
In January 2024, AREXVY was registered by the Therapeutic Goods Administration (TGA) for the immunisation of people aged 60 years and older to prevent lower respiratory tract disease caused by RSV. AREXVY is a recombinant respiratory syncytial virus pre-fusion F protein vaccine. Guidance on its use is yet to come.